|Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study|
LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2013-2019, 2008
|ESMO consensus guidelines for the management of patients with metastatic colorectal cancer|
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
|Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer|
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2006-2012, 2008
|Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer|
World journal of gastroenterology: WJG 12 (2), 192, 2006
|Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous …|
JB Vermorken, J Trigo, R Hitt, P Koralewski, E Diaz-Rubio, F Rolland, ...
Journal of clinical oncology 25 (16), 2171-2177, 2007
|XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer|
J Cassidy, J Tabernero, C Twelves, R Brunet, C Butts, T Conroy, ...
Journal of Clinical Oncology 22 (11), 2084-2091, 2004
|Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data|
FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ...
The lancet oncology 15 (4), 406-414, 2014
|Mechanism and its regulation of tumor-induced angiogenesis|
MK Gupta, RY Qin
World journal of gastroenterology: WJG 9 (6), 1144, 2003
|Wound healing of intestinal epithelial cells|
M Iizuka, S Konno
World journal of gastroenterology: WJG 17 (17), 2161, 2011
|Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines|
D Machover, E Diaz-Rubio, A De Gramont, A Schilf, JJ Gastiaburu, ...
Annals of Oncology 7 (1), 95-98, 1996
|Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer|
J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ...
Journal of clinical oncology 25 (33), 5225-5232, 2007
|Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final …|
E Díaz-Rubio, J Tabernero, A Gómez-España, B Massutí, J Sastre, ...
Journal of clinical oncology 25 (27), 4224-4230, 2007
|Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study|
E Diaz-Rubio, J Sastre, A Zaniboni, R Labianca, H Cortes-Funes, ...
Annals of Oncology 9 (1), 105-108, 1998
|Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables|
J Sastre, ML Maestro, J Puente, S Veganzones, R Alfonso, S Rafael, ...
Annals of Oncology 19 (5), 935-938, 2008
|XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results|
J Cassidy, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong, ...
British journal of cancer 105 (1), 58-64, 2011
|First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase …|
E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ...
The oncologist 17 (1), 15, 2012
|Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium|
J Bellmunt, V Guillem, L Paz-Ares, JL Gonzalez-Larriba, J Carles, ...
Journal of clinical oncology 18 (18), 3247-3255, 2000
|Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF …|
M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ...
Annals of Oncology 14 (6), 833-842, 2003
|Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects|
O Díez, A Osorio, M Durán, JI Martinez‐Ferrandis, M Hoya, R Salazar, ...
Human mutation 22 (4), 301-312, 2003
|Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials|
HT Arkenau, D Arnold, J Cassidy, E Diaz-Rubio, JY Douillard, H Hochster, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2008